99 related articles for article (PubMed ID: 12032698)
1. Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment.
Kircheis R; Wightman L; Kursa M; Ostermann E; Wagner E
Gene Ther; 2002 Jun; 9(11):731-5. PubMed ID: 12032698
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity.
Kircheis R; Ostermann E; Wolschek MF; Lichtenberger C; Magin-Lachmann C; Wightman L; Kursa M; Wagner E
Cancer Gene Ther; 2002 Aug; 9(8):673-80. PubMed ID: 12136428
[TBL] [Abstract][Full Text] [Related]
3. Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer.
Kursa M; Walker GF; Roessler V; Ogris M; Roedl W; Kircheis R; Wagner E
Bioconjug Chem; 2003; 14(1):222-31. PubMed ID: 12526712
[TBL] [Abstract][Full Text] [Related]
4. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application.
Kircheis R; Wightman L; Schreiber A; Robitza B; Rössler V; Kursa M; Wagner E
Gene Ther; 2001 Jan; 8(1):28-40. PubMed ID: 11402299
[TBL] [Abstract][Full Text] [Related]
5. Tissue-dependent factors affect gene delivery to tumors in vivo.
Smrekar B; Wightman L; Wolschek MF; Lichtenberger C; Ruzicka R; Ogris M; Rödl W; Kursa M; Wagner E; Kircheis R
Gene Ther; 2003 Jul; 10(13):1079-88. PubMed ID: 12808438
[TBL] [Abstract][Full Text] [Related]
6. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo.
Kircheis R; Schüller S; Brunner S; Ogris M; Heider KH; Zauner W; Wagner E
J Gene Med; 1999; 1(2):111-20. PubMed ID: 10738575
[TBL] [Abstract][Full Text] [Related]
7. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery.
Ogris M; Brunner S; Schüller S; Kircheis R; Wagner E
Gene Ther; 1999 Apr; 6(4):595-605. PubMed ID: 10476219
[TBL] [Abstract][Full Text] [Related]
8. Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice.
Wolschek MF; Thallinger C; Kursa M; Rössler V; Allen M; Lichtenberger C; Kircheis R; Lucas T; Willheim M; Reinisch W; Gangl A; Wagner E; Jansen B
Hepatology; 2002 Nov; 36(5):1106-14. PubMed ID: 12395320
[TBL] [Abstract][Full Text] [Related]
9. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
Zhu HJ; Zhang ZQ; Zeng XF; Wei SS; Zhang ZW; Guo YL
Cancer Gene Ther; 2004 Apr; 11(4):263-72. PubMed ID: 14963492
[TBL] [Abstract][Full Text] [Related]
10. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA.
Koppu S; Oh YJ; Edrada-Ebel R; Blatchford DR; Tetley L; Tate RJ; Dufès C
J Control Release; 2010 Apr; 143(2):215-21. PubMed ID: 19944722
[TBL] [Abstract][Full Text] [Related]
11. A multifunctional PEI-based cationic polyplex for enhanced systemic p53-mediated gene therapy.
Moffatt S; Wiehle S; Cristiano RJ
Gene Ther; 2006 Nov; 13(21):1512-23. PubMed ID: 16763664
[TBL] [Abstract][Full Text] [Related]
12. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
13. A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene.
Yu W; Pirollo KF; Rait A; Yu B; Xiang LM; Huang WQ; Zhou Q; Ertem G; Chang EH
Gene Ther; 2004 Oct; 11(19):1434-40. PubMed ID: 15229629
[TBL] [Abstract][Full Text] [Related]
14. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.
Gao JQ; Eto Y; Yoshioka Y; Sekiguchi F; Kurachi S; Morishige T; Yao X; Watanabe H; Asavatanabodee R; Sakurai F; Mizuguchi H; Okada Y; Mukai Y; Tsutsumi Y; Mayumi T; Okada N; Nakagawa S
J Control Release; 2007 Sep; 122(1):102-10. PubMed ID: 17628160
[TBL] [Abstract][Full Text] [Related]
15. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Stephens LC; Yu Y; Liu J; Fang B
Gene Ther; 2002 Oct; 9(20):1379-86. PubMed ID: 12365003
[TBL] [Abstract][Full Text] [Related]
16. Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors.
Yazawa H; Murakami T; Li HM; Back T; Kurosaka K; Suzuki Y; Shorts L; Akiyama Y; Maruyama K; Parsoneault E; Wiltrout RH; Watanabe M
Cancer Gene Ther; 2006 Nov; 13(11):993-1001. PubMed ID: 16763608
[TBL] [Abstract][Full Text] [Related]
17. Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model.
Sweeney P; Karashima T; Ishikura H; Wiehle S; Yamashita M; Benedict WF; Cristiano RJ; Dinney CP
Cancer Res; 2003 Jul; 63(14):4017-20. PubMed ID: 12874000
[TBL] [Abstract][Full Text] [Related]
18. Optical imaging of transferrin targeted PEI/DNA complexes in living subjects.
Hildebrandt IJ; Iyer M; Wagner E; Gambhir SS
Gene Ther; 2003 May; 10(9):758-64. PubMed ID: 12704414
[TBL] [Abstract][Full Text] [Related]
19. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B
Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263
[TBL] [Abstract][Full Text] [Related]
20. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors.
Dufès C; Keith WN; Bilsland A; Proutski I; Uchegbu IF; Schätzlein AG
Cancer Res; 2005 Sep; 65(18):8079-84. PubMed ID: 16166279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
